Literature DB >> 6744419

Rapid loss of sensitivity of mitogen-induced lymphocyte activation to inhibition by cyclosporin A.

J E Kay, C R Benzie.   

Abstract

The ability of the immunosuppressive drug cyclosporin A (CS-A) to inhibit the activation of lymphocytes by phytohaemagglutinin (PHA) and concanavalin A (Con A) is progressively lost over the 8-hr period following mitogen addition. This process is dependent on the presence of Ca2+ in the culture medium and is complete at a time when activation still requires the continued presence of the mitogen. While inhibition by CS-A is reduced to some extent by lymphokines produced by mitogen-activated cultures, the initial loss of sensitivity to CS-A is too complete and too rapid to be accounted for in this way. We conclude that CS-A inhibits an early Ca2+-dependent step in mitogen-induced activation that is not in itself sufficient to commit the cells to initiate proliferation, but is required for later steps in the activation process, including lymphokine production.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6744419     DOI: 10.1016/0008-8749(84)90145-x

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  4 in total

1.  In vitro and in vivo action of cyclosporin A on the induction of human interleukin-2 receptor alpha and beta chains.

Authors:  S Caillat-Zucman; L Chatenoud; J F Bach
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

2.  Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506.

Authors:  J E Kay; C R Benzie; M R Goodier; C J Wick; S E Doe
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

3.  T-cell activation influences initial DNA synthesis of simian immunodeficiency virus in resting T lymphocytes from macaques.

Authors:  P S Polacino; H A Liang; E J Firpo; E A Clark
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

4.  Lymphocyte activation by OKT3: cyclosporine sensitivity and synergism with phorbol ester.

Authors:  J E Kay; C R Benzie
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.